SEC accuses Merck exec of insider trading

In a civil suit filed in Philadelphia, the SEC accused James Self, 45, an executive director at Merck, of feeding his business school buddy and former hedge fund manager Stephen Goldfield, 46, the details of a 2007 Merck deal to buy drug firm MedImmune. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.